Kinase Inhibitor in Autoimmune Diseases Market Snapshot (2023 to 2033)
The global kinase inhibitor in autoimmune diseasesmarket is expected to be valued at US$ 47,430 Million in 2023 and is anticipated to expand at a CAGR of 5.4%. Owing to the technological advances in healthcare the market is likely to propel to US$ 80,252 Million by 2033.
The increasing healthcare spending and increasing awareness pertaining to autoimmune diseases are likely to drive the growth of the kinase inhibitor in the autoimmune diseases market in the forecast period.
Report Attribute
Details
Expected Market Value (2023)
US$ 47,430 Million
Projected Forecast Value (2033)
US$ 80,252 Million
Global Growth Rate (2023 to 2033)
5.4% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Kinase Inhibitor in Autoimmune Diseases Market Revenue Analysis 2018 to 2022 vs. Future Outlook 2023 to 2033
The kinase inhibitor in the autoimmune diseasesmarket is expected to gain market growth in the forecast period of 2023 to 2033. Latest market analysis by FMI the market is to grow at a CAGR of 5.4% in the above-mentioned forecast period.
Autoimmune diseases occur when the immune system attacks one or more cells of the body which are functioning normally owing to the irregularities. The mis-functioning of the immune system is a result of the failure to recognize immune cells, tissues, and organs and produce autoantibodies targeting these cells.
There are massive technological developments happening in the healthcare sector, especially in the area of autoimmune disease treatment. Companies are making use of this technology to develop much more evolved forms of tyrosine kinase inhibitors. This might increase the demand for kinase inhibitors for cancer treatment during the forecast period. Presently, pharmaceutical companies are investing heavily in Research and Development to develop enhanced kinase inhibitors. This is currently driving the market growth. The global kinase inhibitor in the autoimmune diseasesmarket rose at a CAGR of 5.1% from 2018 to 2022.
What Market Trends Are Influencing the Kinase Inhibitor in Autoimmune Diseases Market?
Growing Healthcare Spending to Drive the Kinase Inhibitor in Autoimmune Disease Market
The increasing prevalence of autoimmune and chronic diseases including rheumatic arthritis, psoriatic arthritis, ulcerative colitis, etc. is expected to drive the growth of kinase inhibitors in the autoimmune disease market.
Additionally, the increasing number of special designations for drugs in the pipeline is also expected to fuel the growth of the market. Kinase Inhibitor in the autoimmune disease market is primarily driven by a few key factors such as the rising prevalence of autoimmune disease, patient awareness regarding rising healthcare concerns, increase in healthcare expenditure.
The considerable efforts by the governments as well as the private players across the world in improving, rebuilding, and innovating healthcare infrastructure across the globe are also translating into various worthwhile development opportunities for the players in the global kinase inhibitor autoimmune diseases market in coming years. Rising government initiatives and the increase in automation technologies lead to higher sensitivity, faster and easy performing diagnosis test results, and prevention of disease.
Increased Research and Development Drive the Market During the Forecast Period
The rising prevalence of autoimmune diseases is likely to fuel the growth of the kinase inhibitor in the autoimmune disease market. Therefore, a consistent increase in the autoimmune patient population across the world has been identified as one of the major factors driving the kinase inhibitor in the autoimmune disease market.
The pharmaceutical companies on Research and Development to come up with potential kinase inhibitors for the treatment of autoimmune diseases are driving the growth of kinase inhibitors in the autoimmune disease market, globally.More than 400 diseases have been associated directly or indirectly with protein kinase. The success of kinase inhibitors in treating autoimmune diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis has showcased their therapeutic potential. This success, coupled with a greater understanding of inflammatory signaling cascades, led to kinase inhibitors taking center stage to pursue new anti-inflammatory agents for the treatment of immune-mediated diseases.
The expected launch of emerging therapies such as SHR0302, Ruxolitinib, Branebrutinib, Ritlecitinib, Ritlecitinib/PF-06650833/ Tofacitinib, Abrocitinib, PF-06826647, Brepocitinib, SHR0302, Ruxolitinib, Branebrutinib likely to drive the market during the forecast period.
Find your sweet spots for generating winning opportunities in this market.
Which Factors Are Restraining the Growth in the Kinase Inhibitor in Autoimmune Diseases Market?
Lack of Skilled Professional May Hamper the Market Growth
The high cost associated with the latest clinical trials and complex approvals processes is acting as a major obstruction to the growth of kinase inhibitors in the autoimmune diseases market. On the other hand, the dearth of skilled professionals and technicians as well as the rise in the lack of understanding about the basic aetiology of autoimmune disorders may restrict the growth in the global kinase inhibitor autoimmune diseases market in near future.
However, modernization, as well as technological advancements in medical and healthcare devices as well as the constant efforts by the industry players on geographical as well as product offerings expansion, are anticipated to bolster the rising demand in the global kinase inhibitor in autoimmune diseases market over the forecast period.
Country-Wise Insights
What Makes the USA an Attractive Market for Kinase Inhibitors in Autoimmune Diseases?
Increasing Rate of Autoimmune Diseases in the USA to Propel the Market Growth
The USA is estimated to account for over 5.2% of the North American market in 2022. The growth of the market in the region is attributed to the increasing prevalence of autoimmune diseases. North America holds a leading position in the Kinase inhibitor in the autoimmune disease Market due to the growing incidence of autoimmune disorders such as rheumatoid arthritis, and diabetes type I in the region.
According to the National Institutes of Health, up to23.5 million Americans (more than seven percent of the population) suffer from an autoimmune disease - and the prevalence is rising.
Government initiatives such as the Affordable Care Act and Patient Protection Act are further fueling the growth of the market size of kinase inhibitors in autoimmune diseases.
Why is the Kinase Inhibitor in Autoimmune Diseases Market in Europe Expected to Be Highly Opportunistic?
Rising Investments in Research and Development Driving Growth in Europe Market
The Europe kinase inhibitors in the autoimmune disease market are expected to rise at a CAGR of 5.1% from 2023 to 2033. Europe is expected to have the second-largest market for global kinase inhibitors in the autoimmune disease market. Increasing awareness among people about diseases is also a major factor that may boost the growth of the market in this region.
The growing advancement of healthcare infrastructure, increasing per-capita income, and MNCs strengthening their distribution network all these factors also boost the market growth. Increased penetration of new technologies such as potable diagnostic equipment and novel biomarkers are contributing largely to the market growth of Europe.
Which Factors Are Supporting Growth of the Kinase Inhibitor in the Autoimmune Diseases Market in Asia Pacific?
Rapid development in pharmaceuticals to drive the market growth in Asia Pacific
Asia Pacific is anticipated to experience the fastest growth in the kinase inhibitors in the autoimmune diseases market as a result of an increase in the prevalence of chronic diseases, and autoimmune diseases. Asia is expected to be the fastest-growing market in the upcoming years. This is due to the rising aging population and improving healthcare infrastructure in this region. Moreover, rising awareness about better healthcare facilities is also driving the growth of the autoimmune disease treatment market in the region.
Rising awareness about healthcare and increasing investments in Research and Development in pharmaceutical and life sciences sectors are some of the key factors driving the growth of the global kinase inhibitor in the autoimmune diseases market. However, in the Middle East and Africa market growth is expected to be limited due to slow economic growth, underdeveloped infrastructure, and lower access to technological advancement.
Country-wise Forecast CAGRs for the Kinase Inhibitor in Autoimmune Diseases Market
UK
5.1%
India
4.8%
South Korea
4.9%
China
5.0%
USA
5.2%
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category wise Insights
Based on Drug Type, Which Is the Most Prominent Segment in The Kinase Inhibitor in Autoimmune Diseases Market?
Anti-inflammatory Drugs Segment remains dominant among other Drugs Types
Anti-inflammatory Drugs (NSAIDs) dominated the industry in 2023. The anti-inflammatory segment dominated the global market in 2023 with a revenue share of over 45.3%. This is attributed to the high level of penetration of drugs, and availability at lower cost in comparison to drugs of other classes.
Some of the drugs to treat autoimmune diseases include NSAID, DMARD, biologic DMARD, and 5-ASA. Other therapies such as bridge therapy, topical therapy, phototherapy, and recombinant technology are also used for the treatment of these diseases. On the other hand, corticosteroids anticipated to witness the fastest growth over the forecast period are typically used to treat rheumatologic diseases, like rheumatoid arthritis, lupus, or vasculitis.
Start-up Scenario
How do New Entrants Contribute to the Kinase Inhibitor in Autoimmune Diseases Market?
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the kinase inhibitor in the autoimmune diseases market.
Some of the start-ups in the kinase inhibitor in autoimmune diseases market include-
Avila Therapeutics focuses on the design and development of targeted covalent drugs. The company's product pipeline has been built using its proprietary Avilomics platform and is currently focused on cancer, viral infection, and autoimmune disease. Avila's most advanced product candidate, AVL-292, a potential treatment for cancer and autoimmune diseases, is currently in Phase 1 clinical testing. Avila was acquired by Celgene in March 2012.
Polymed biopharmaceuticals - Developer of small molecule therapeutics for cancer and autoimmune diseases. The company has protein degradation therapeutics HPB-001 for cancer and HPB-002 for autoimmune disease. Also, has a protein kinase inhibitor HPB-003 which provides an anti-inflammation effect.
Sareum Holdings discovers and develops small-molecule therapeutics for cancer and autoimmune diseases. The company has developed SKIL (Sareum Kinase Inhibitor Library) platform for drug discovery which is used to inhibit many different kinases. The company's other product includes TYK2 inhibitor which is used for the treatment of autoimmune diseases such as psoriasis, lupus, and colon cancer.
Dynamix provides a portfolio of drug discovery and development. Its drug candidate is PKM2 is in the preclinical trial for cancer metabolism, It also develops kinase inhibitors such as SYK and JYK3 for cancer and autoimmune disease therapy. Its DynamixFit is the proprietary technology that helps in 3D-based in silico drug design.
Competitive Landscape
The professional survey study carefully analyses the operations and overview of the corporate structures and functioning of the leading and major manufacturers and players functional within the global kinase inhibitor in the autoimmune diseases market. It assesses its product offerings, financial outlook, sales, revenue, and growth over the forecast period.
Some of the leading manufacturers and players assessed in the global kinase inhibitor in autoimmune treatment market include Pfizer, Reistone Biopharma, Eli Lily and Incyte Corporation, AbbVie, Gilead Sciences, Astellas Pharma, Japan Tobacco and Torii Pharmaceutical, Incyte Corporation, Bristol Myers Squibb, Galapagos NV, and others
Manufacturers and players functional in the global kinase inhibitor in autoimmune diseases market are adopting various corporate growth strategies such as new product launches, mergers and acquisitions, and geographical expansion, among others.
In December 2022 - AbbVie and HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced an exclusive worldwide collaboration and option to license agreement for HotSpot's discovery-stage IRF5 program for the treatment of autoimmune diseases.
In August 2021 -Reistone Biopharma, focused on development of treatments for immune & inflammation-related diseases, announced positive top-line results from a Phase 2 study evaluating the safety and effectiveness of once-daily SHR0302 in adults with alopecia areata (AA). Treatment was well tolerated, and safety was consistent with other JAK1 inhibitors. AA is an autoimmune disease that causes hair loss in patches or sometimes complete hair loss, leading to high psychological burden.
Key Segments Covered in the Kinase Inhibitor in Autoimmune Diseases Industry Survey
Kinase Inhibitor in Autoimmune Diseases Market by Treatment:
Physical therapy
Treatment of Deficiency
Surgery
Kinase Inhibitor in Autoimmune Diseases Market by Drug:
Anti-inflammatory Drugs
Corticosteroids
Pain-killing Medications
Immunosuppressants
Kinase Inhibitor in Autoimmune Diseases Market by Region:
North America
Latin America
Europe Kinase
Asia Pacific
Middle East & Africa
Frequently Asked Questions
What is the expected valuation of the kinase inhibitor in the autoimmune diseases market?
The global kinase inhibitor in autoimmune diseases market is likely to reach a valuation of US$ 47,430 Million by the end of 2023.
Who are the key players in the kinase inhibitor in autoimmune diseases market?
Pfizer, Reistone Biopharma, Eli Lily and Incyte Corporation, AbbVie, Gilead Sciences, Astellas Pharma are some of the key players in the global kinase inhibitor in autoimmune diseases market
What are the future prospects for kinase inhibitor in autoimmune diseases market sales?
Sales of the kinase inhibitor in autoimmune diseases market are likely to expand at 5.4% CAGR through 2033
Which are the top 5 countries driving demand for biopharma plastics?
The USA, Canada, Japan, China, & Germany are expected to drive most of the demand for kinase inhibitor in autoimmune diseases market
What will be the global kinase inhibitor in autoimmune diseases market revenue total by 2033?
By the end of 2033, the global market for kinase inhibitor in autoimmune diseases market is predicted to reach a valuation of US$ 80,252 Million
Table of Content
1. Executive Summary | Kinase Inhibitor in Autoimmune Diseases Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Physical Therapy
5.3.2. Treatment for Deficiency
5.3.3. Surgery
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Drug, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug, 2023 to 2033
6.3.1. Anti-inflammatory Drugs
6.3.2. Corticosteroids
6.3.3. Pain-killing Medications
6.3.4. Immunosuppressants
6.4. Y-o-Y Growth Trend Analysis By Drug, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Drug, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5.Middle East and Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. United States of America
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By Drug
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By Drug
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By Drug
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By Drug
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By Drug
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By Drug
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Treatment
11.2.3. By Drug
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By Drug
11.4. Key Takeaways
12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Treatment
12.2.3. By Drug
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By Drug
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. United States of America
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Treatment
13.1.2.2. By Drug
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Treatment
13.2.2.2. By Drug
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Treatment
13.3.2.2. By Drug
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Treatment
13.4.2.2. By Drug
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Treatment
13.5.2.2. By Drug
13.6. United Kingdom
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Treatment
13.6.2.2. By Drug
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Treatment
13.7.2.2. By Drug
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Treatment
13.8.2.2. By Drug
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Treatment
13.9.2.2. By Drug
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Treatment
13.10.2.2. By Drug
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Treatment
13.11.2.2. By Drug
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Treatment
13.12.2.2. By Drug
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Treatment
13.13.2.2. By Drug
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Treatment
13.14.2.2. By Drug
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Treatment
13.15.2.2. By Drug
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Treatment
13.16.2.2. By Drug
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Treatment
13.17.2.2. By Drug
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Treatment
13.18.2.2. By Drug
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Treatment
13.19.2.2. By Drug
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Treatment
13.20.2.2. By Drug
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Treatment
14.3.3. By Drug
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Pfizer
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Reistone Biopharma
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Eli Lily and Incyte Corporation
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. AbbVie
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Gilead Sciences
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Astellas Pharma
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Japan Tobacco and Torii Pharmaceutical
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Incyte Corporation
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Bristol Myers Squibb
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Galapagos NV
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used17. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 12: Europe Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Asia Pacific Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 15: Asia Pacific Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 16: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 18: MEA Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Drug, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033
Figure 14: Global Market Attractiveness by Drug, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by Drug, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033
Figure 29: North America Market Attractiveness by Drug, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by Drug, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033
Figure 44: Latin America Market Attractiveness by Drug, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 47: Europe Market Value (US$ Million) by Drug, 2023 to 2033
Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 55: Europe Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 59: Europe Market Attractiveness by Drug, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: Asia Pacific Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 62: Asia Pacific Market Value (US$ Million) by Drug, 2023 to 2033
Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 70: Asia Pacific Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 73: Asia Pacific Market Attractiveness by Treatment, 2023 to 2033
Figure 74: Asia Pacific Market Attractiveness by Drug, 2023 to 2033
Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 76: MEA Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 77: MEA Market Value (US$ Million) by Drug, 2023 to 2033
Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 83: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 84: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 85: MEA Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 86: MEA Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 87: MEA Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 88: MEA Market Attractiveness by Treatment, 2023 to 2033
Figure 89: MEA Market Attractiveness by Drug, 2023 to 2033
Figure 90: MEA Market Attractiveness by Country, 2023 to 2033
